Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma

NCT01340209 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

285

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: Tiotropium Respimat
DRUG: Placebo Respimat
DRUG: Tiotropium Respimat

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]